Dr. Yarema joined Poseida as the President, Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. Prior to Poseida she served as Chief Commercial Officer at Atara Biotherapeutics, where she led the commercialization of EBVALLO™️, which became the world’s first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma. Earlier in her career, Dr. Yarema worked at Novartis and McKinsey & Company. She serves on the boards of directors of the Celiac Disease Foundation and the Alliance for Regenerative Medicine.